This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

INVENT Ventures And Heliant Ventures Seek To Accelerate Personalized Medicine Research With Seed Round Investment In Sanguine BioSciences

VALENCIA, Calif., Feb. 21, 2013 /PRNewswire/ -- SANGUINE BIOSCIENCES, INC. ("Sanguine"), a biotechnology company empowering patients in biomedical research, has announced the closing of its seed financing round, led by INVENT Ventures and Heliant Ventures.

Sanguine engages research subjects through social media and non-profit advocacy, and schedules blood draws, which are then processed into DNA, RNA, cells, plasma, and serum, to be used as biomedical research materials at pharmaceutical companies and research institutions. The company has developed the infrastructure to provide research subjects with information on how their samples were used, in order to ultimately increase trust and information flow back to researchers.

"Sanguine has experienced significant growth since Q4 2012, both in terms of revenues and number of research subjects. The successful completion of the laboratory and regulatory infrastructure allowed us the opportunity to open our doors to research participants, both healthy, and diagnosed with an ailment(s), and to researchers at numerous pharmaceutical companies and academic institutions.

We plan to use the funds raised in the seed round to further develop our internal infrastructure in order to safely and efficiently collect, process, document, and store up to 1,000 blood samples each month across the west coast. We are looking forward to scaling up and providing researchers with the samples they need to perform their investigations, while also providing patients with the knowledge of how their samples have impacted Personalized Medicine research." Brian Neman, CEO

"Sanguine is building products and processes that will revolutionize personalized medicine research," said INVENT CEO Bryce Knight. "We are thrilled to support Sanguine and its exceptional team through their growth at the forefront of multiple rapidly-growing markets." 

"We are very happy to jointly lead this round of investment and to be connected to a company at the forefront of its industry. Sanguine's business model achieves that unique harmony between placing the patient interests first while still generating returns for all its stakeholders," said Heliant Ventures Director Ben Weiss.  "Full credit to the hard-working Sanguine team for reaching this important milestone and we look forward to supporting the company to realize its exciting growth potential."

About Sanguine BioSciences Inc.Sanguine BioSciences is a biotechnology company bridging the gap between patients and researchers by providing transparency throughout the personalized medicine R&D process. Sanguine collects and de-identifies patient-derived data in the form of biospecimen and physician and self-reported information. These data are generated and then made available to researchers involved in drug and biomarker research and discovery. ( http://sanguinebio.com)

About INVENT VenturesINVENT Ventures Inc. (OTC: IDEA) is a publicly traded venture fund that builds and invests in transformative technology businesses. INVENT primarily operates in markets of digital media, consumer Internet, and social networking, and has built six companies at various stages of development. ( www.invent.vc.)

About Heliant VenturesEstablished in 2012, Heliant Ventures is a venture capital fund backed by leading investors across Asia and Australia. ( www.heliantventures.com)

SOURCE Sanguine BioSciences, Inc.; INVENT Ventures, Inc.

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,157.01 +25.04 0.15%
S&P 500 2,001.93 +2.95 0.15%
NASDAQ 4,562.4050 +9.6460 0.21%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs